Austria sits among the more conservative jurisdictions in the European cannabis conversation. Recreational cannabis remains prohibited under the country’s Narcotic Substances Act, and unlike neighbouring Germany or the Czech Republic, Austrian patients cannot be prescribed cannabis flower. A narrow medical channel does exist, however, built around finished cannabis-based medicines, and the framework around hemp and CBD has gradually widened. For operators, investors and policy professionals, Austria is best read as a tightly regulated jurisdiction with a small but stable medical pathway and limited near-term prospects for adult-use reform.
Background: Austrian cannabis policy in context
Austria’s primary statute is the Suchtmittelgesetz, or Narcotic Substances Act (SMG), which entered into force in 1998 and brings the country into line with the United Nations Single Convention on Narcotic Drugs. Cannabis, cannabis resin and tetrahydrocannabinol (THC) are listed as controlled substances. The Act prohibits cultivation, production, possession, supply and import for non-medical purposes.
The Austrian Agency for Health and Food Safety (AGES) is the only body permitted to cultivate cannabis on Austrian soil, a monopoly granted by the SMG and operated through its subsidiary AGES Medizinmarktaufsicht. AGES supplies extracts and the cannabinoid dronabinol to licensed pharmaceutical manufacturers but does not provide cannabis flower to patients or pharmacies. This single feature most distinguishes the Austrian medical model from the German, Czech and Italian frameworks, in which dried flower is a recognised dispensing format.
Possession for personal use is illegal but handled with proportionality. Under the principle of “Therapie statt Strafe” (treatment instead of punishment), prosecutors typically suspend proceedings for first-time possession of small quantities of cannabis where no other offence is involved. The conviction is avoided if the person engages with health authorities. The practical effect is decriminalisation in many cases, although it is not codified as a defined possession threshold in the way it is in some other European jurisdictions.
Current legal status: what is and is not permitted
Three regulated areas define the legal cannabis landscape in Austria.
Medical cannabis-based medicines
Austrian doctors can prescribe a defined set of cannabis-based medicines. These include nabiximols (sold as Sativex) for multiple sclerosis-related spasticity, dronabinol as a magistral preparation compounded by pharmacies, the synthetic cannabinoid nabilone, and cannabidiol (Epidyolex) for specified forms of epilepsy. Reimbursement by the social health insurance system is conditional and assessed case by case, with cost coverage more readily granted for licensed medicines than for magistral dronabinol preparations. Cannabis flower is not an authorised dispensing format.
Industrial hemp and CBD
Hemp cultivation is permitted for varieties listed in the EU Common Catalogue of Agricultural Plant Species, where THC content does not exceed 0.3%. CBD products are widely sold but their legal classification is restrictive. Austria has historically required CBD oils, flowers and edibles to be marketed as “aromatic products” or cosmetics rather than food or food supplements, in line with the European Commission’s novel-food position. Selling CBD products with explicit consumption claims has prompted enforcement action by Austrian food authorities in past years.
Adult-use cannabis
Adult-use cannabis is not legal in Austria. There is no licensed retail channel, no cannabis social-club framework and no draft legislation moving through the National Council that would create one. Reform debate has been low-key relative to Germany or the Czech Republic, and successive Austrian governments have signalled preference for a public-health approach grounded in decriminalisation rather than commercial supply. Discussions among health policy experts have continued, but no implementing bill is currently in progress.
What this means for businesses
For licensed pharmaceutical operators, Austria functions as a small but technically demanding medical market. The reliance on finished medicines and pharmacy-compounded magistral preparations places the country firmly within the EU pharmaceutical regulatory perimeter, with corresponding requirements around Good Manufacturing Practice, narcotic controls and cost-effectiveness review. New market entry is generally pursued through partnerships with Austrian pharmaceutical wholesalers and existing manufacturers rather than through direct licensing applications.
For hemp and CBD operators, Austria offers reasonable market access provided products are positioned and labelled in line with Austrian and EU rules. Companies marketing CBD as an ingestible supplement should expect closer scrutiny than in some other member states. Investors should also note that Austria’s market size is modest by European standards, and commercial scale typically requires a wider European footprint.
For investors evaluating the broader regional picture, Austria is best read as a stable but cautious jurisdiction. Reform momentum exists in Germany, the Czech Republic and Switzerland; Austria’s policy direction has lagged. Investment theses anchored on near-term Austrian reform should be treated with scepticism. Austria does, however, offer high-quality regulatory infrastructure, a developed pharmaceutical sector and a well-educated workforce, which support its role as a credible operating base for companies serving the wider central European medical market.
Key considerations and what to watch
Three issues will shape Austrian cannabis policy through 2026 and beyond. The first is the European context: as Germany’s medical and pilot adult-use frameworks mature, and as the Czech Republic continues to debate cannabis-association models, pressure will build on neighbouring jurisdictions to clarify their own positions. The second is the regulatory treatment of novel cannabinoids: Austria has taken a cautious line on HHC and other semi-synthetic compounds, broadly in step with neighbouring countries. The third is reimbursement: incremental expansion of social-insurance coverage for cannabis-based medicines would matter more to operators than headline reform, given the structure of the existing market.
For broader regional context, see Cannabis Europa’s analysis of European cannabis regulations in 2026, which sets the Austrian market alongside developments in Germany, France and the United Kingdom. Senior decision-makers will continue this conversation at Cannabis Europa London 2026, 26–27 May at The Barbican.